Abstract
Introduction Metal exposure has been associated with higher risk of neurodegenerative disorders such as Alzheimer’s disease (AD). We examined the potential link between welding-related metal co-exposure (e.g., Fe, Mn, Pb) and AD-related structural and neurobehavioral metrics.
Methods Subjects with (welders; n=42) or without (controls; n=31) a history of welding were examined. Metal exposure was estimated by exposure questionnaires and whole blood metal levels. Brain metal accumulations were estimated by MRI R1 (Mn) and R2* (Fe) in the caudate, putamen, globus pallidus, red nucleus (RN), and hippocampus. AD-related structural differences were assessed by volume and diffusion tensor imaging metrics in the hippocampus, and neurobehavioral aspects by learning/memory task scores.
Results Compared to controls, welders displayed higher blood metal levels (p’s <0.004) and R2* values in the caudate and RN (p’s<0.024). Caudate R2* values were associated with blood Fe (p=0.043), whereas RN R2* values were correlated with blood Pb (p=0.003). Welders had higher hippocampal mean diffusivity (MD; p=0.011) and lower Story Recall scores (p=0.049), but no difference in volume or domain-wise learning/memory performance (p’s>0.117). Group differences in hippocampal MD and Story Recall scores were greater with higher RN R2* values (p’s<0.016). Moreover, RN R2* values reflected an indirect link between blood Pb and hippocampal MD (p=0.036) across both groups.
Discussion Welders had hippocampal structural and learning/memory performance differences similar to those in AD-at-risk populations. These AD-like differences in welders may, in part, be linked to Pb exposure reflected by higher RN R2* levels at the brain level.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by NIH grants R01 ES019672, R01 NS060722, U01 NS082151 and NS112008, the Hershey Medical Center General Clinical Research Center (National Center for Research Resources, UL1 TR002014), the Penn State College of Medicine Translational Brain Research Center, the PA Department of Health Tobacco CURE Funds, and the National Research Foundation of Korea (2019R1G1A109957511).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted at PennStateHealth (PSH) in compliance with the ethical principles of the Declaration of Helsinki and guidelines for Good Clinical Practice issued by the International Conference on Harmonization. It was reviewed and approved by the PSH Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
